Iron availability modulates aberrant splicing of ferrochelatase through the iron- and 2-oxoglutarate dependent dioxygenase Jmjd6 and U2AF65

Blood Cells, Molecules, and Diseases

Volumn 51, Issue 3, 2013, Pages 151-161

  Barman Aksözen, Jasmin ^a,b   Béguin, Chantal ^a   Dogar, Afzal M ^c   Schneider Yin, Xiaoye ^a   Minder, Elisabeth I ^a  

^a Institute of Laboratory Medicine   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c ETH ZURICH   (Switzerland)

Author keywords

Aberrant splicing; Ferrochelatase; Iron; Jmjd6; U2AF65

Indexed keywords

2 OXOGLUTARIC ACID; DIOXYGENASE; FERROCHELATASE; IRON; JUMONJI DOMAIN CONTAINING PROTEIN 6; LYSINE; MESSENGER RNA; MESSENGER RNA PRECURSOR; PROTEIN; SMALL INTERFERING RNA; U2 SNRNP AUXILIARY FACTOR 65; UNCLASSIFIED DRUG;

ALLELE; ALTERNATIVE RNA SPLICING; ARTICLE; ASYMPTOMATIC DISEASE; CELL STRAIN K 562; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME DEFICIENCY; ENZYME REGULATION; ERYTHROPOIETIC PROTOPORPHYRIA; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; IRON DEFICIENCY; LYMPHOBLASTOID CELL LINE; PRIORITY JOURNAL; REGULATED UNPRODUCTIVE SPLICING AND TRANSLATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ABERRANT SPLICING; FERROCHELATASE; IRON; JMJD6; U2AF(65);

ALTERNATIVE SPLICING; BASE SEQUENCE; CASE-CONTROL STUDIES; CELL LINE; COBALT; DEFEROXAMINE; FERROCHELATASE; GENE EXPRESSION REGULATION; GENE ORDER; GENE SILENCING; GENOTYPE; HUMANS; INTRONS; IRON; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; K562 CELLS; KETOGLUTARIC ACIDS; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEAR PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTOPORPHYRIA, ERYTHROPOIETIC; RIBONUCLEOPROTEINS; RNA INTERFERENCE; RNA, MESSENGER; SEQUENCE ALIGNMENT;

EID: 84881025042     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2013.05.008     Document Type: Article

References (45)

1. Abràmoff M.D., Magalhaes P.J., Ram S.J. Image processing with ImageJ. Biophotonics Int. 2004, 11:36-42.
2. Anderson K., Sassa S., Bishop D.F., Desnick R.J. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. The Metabolic and Molecular Basis of Inherited Disease 2001, 2991-3062. McGraw-Hill, New York. C.R. Scriver, M. Beaugrand, W.S. Sly, D. Valle (Eds.).
3. Andersson L.C., Nilsson K., Gahmberg C.G. K562-a human erythroleukemic cell line. Int. J. Cancer 1979, 23:143-147.
4. Asakura K., Sasaki S., Murakami K., et al. Iron intake does not significantly correlate with iron deficiency among young Japanese women: a cross-sectional study. Public Health Nutr. 2009, 12:1373-1383.
5. Boeckel J.N., Guarani V., Koyanagi M., et al. Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:3276-3281.
6. Burden A.E., Wu C., Dailey T.A., et al. Human ferrochelatase: crystallization, characterization of the [2Fe-2S] cluster and determination that the enzyme is a homodimer. Biochim. Biophys. Acta 1999, 1435:191-197.
7. Crooks D.R., Ghosh M.C., Haller R.G., et al. Posttranslational stability of the heme biosynthetic enzyme ferrochelatase is dependent on iron availability and intact iron-sulfur cluster assembly machinery. Blood 2010, 115:860-869.
8. Dorner M., Zucol F., Berger C., et al. Distinct ex vivo susceptibility of B-cell subsets to epstein-barr virus infection according to differentiation status and tissue origin. J. Virol. 2008, 82:4400-4412.
9. Ennis H.L., Lubin M. Cycloheximide: aspects of inhibition of protein synthesis in mammalian cells. Science 1964, 146:1474-1476.
10. Ferreira G.C., Franco R., Lloyd S.G., et al. Mammalian ferrochelatase, a new addition to the metalloenzyme family. J. Biol. Chem. 1994, 269:7062-7065.
11. Fujita P.A., Rhead B., Zweig A.S., et al. The UCSC Genome Browser database: update 2011. Nucleic Acids Res. 2011, 39:D876-D882.
12. Gouya L., Martin-Schmitt C., Robreau A.M., et al. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am. J. Hum. Genet. 2006, 78:2-14.
13. Gouya L., Puy H., Robreau A.M., et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat. Genet. 2002, 30:27-28.
14. Guth S., Martinez C., Gaur R.K., Valcarcel J. Evidence for substrate-specific requirement of the splicing factor U2AF(35) and for its function after polypyrimidine tract recognition by U2AF(65). Mol. Cell. Biol. 1999, 19:8263-8271.
15. Imamachi N., Tani H., Akimitsu N. Up-frameshift protein 1 (UPF1): multitalented entertainer in RNA decay. Drug Discov. Ther. 2012, 6:55-61.
16. Iwata J., Nishikaze O. New micro-turbidimetric method for determination of protein in cerebrospinal fluid and urine. Clin. Chem. 1979, 25:1317-1319.
17. Jenkins J.L., Laird K.M., Kielkopf C.L. A broad range of conformations contribute to the solution ensemble of the essential splicing factor U2AF(65). Biochemistry 2012, 51:5223-5225.
18. Jurica M.S., Moore M.J. Pre-mRNA splicing: awash in a sea of proteins. Mol. Cell 2003, 12:5-14.
19. Karolchik D., Hinrichs A.S., Furey T.S., et al. The UCSC table browser data retrieval tool. Nucleic Acids Res. 2004, 32:D493-D496.
20. Kent W.J. BLAT-the BLAST-like alignment tool. Genome Res. 2002, 12:656-664.
21. Kent W.J., Sugnet C.W., Furey T.S., et al. The human genome browser at UCSC. Genome Res. 2002, 12:996-1006.
22. Kim K., Ryu J.H., Park J.W., et al. Induction of a SSAT isoform in response to hypoxia or iron deficiency and its protective effects on cell death. Biochem. Biophys. Res. Commun. 2005, 331:78-85.
23. Koeffler H.P., Golde D.W. Human myeloid leukemia cell lines: a review. Blood 1980, 56:344-350.
24. Kohgo Y., Ikuta K., Ohtake T., et al. Body iron metabolism and pathophysiology of iron overload. Int. J. Hematol. 2008, 88:7-15.
25. Kumar S., Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol. Lett. 2005, 157:175-188.
26. Larkin M.A., Blackshields G., Brown N.P., et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948.
27. Lewis B.P., Green R.E., Brenner S.E. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:189-192.
28. Lozzio C.B., Lozzio B.B. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975, 45:321-334.
29. Luxton R.W., Patel P., Keir G., Thompson E.J. A micro-method for measuring total protein in cerebrospinal fluid by using benzethonium chloride in microtiter plate wells. Clin. Chem. 1989, 35:1731-1734.
30. Mackereth C.D., Madl T., Bonnal S., et al. Multi-domain conformational selection underlies pre-mRNA splicing regulation by U2AF. Nature 2011, 475:408-411.
31. Magness S.T., Tugores A., Diala E.S., Brenner D.A. Analysis of the human ferrochelatase promoter in transgenic mice. Blood 1998, 92:320-328.
32. Pacheco T.R., Coelho M.B., Desterro J.M., et al. In vivo requirement of the small subunit of U2AF for recognition of a weak 3' splice site. Mol. Cell. Biol. 2006, 26:8183-8190.
33. Paillusson A., Hirschi N., Vallan C., et al. A GFP-based reporter system to monitor nonsense-mediated mRNA decay. Nucleic Acids Res. 2005, 33:e54.
34. Ponka P. Cellular iron metabolism. Kidney Int. Suppl. 1999, 69:S2-S11.
35. Rose N.R., McDonough M.A., King O.N., et al. Inhibition of 2-oxoglutarate dependent oxygenases. Chem. Soc. Rev. 2011, 40:4364-4397.
36. Rosenbloom K.R., Dreszer T.R., Pheasant M., et al. ENCODE whole-genome data in the UCSC Genome Browser. Nucleic Acids Res. 2010, 38:D620-D625.
37. Rufenacht U.B., Gouya L., Schneider-Yin X., et al. Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria. Am. J. Hum. Genet. 1998, 62:1341-1352.
38. Schneider-Yin X., Gouya L., Dorsey M., et al. Mutations in the iron-sulfur cluster ligands of the human ferrochelatase lead to erythropoietic protoporphyria. Blood 2000, 96:1545-1549.
39. Schneider-Yin X., Harms J., Minder E.I. Porphyria in Switzerland, 15years experience. Swiss Med. Wkly. 2009, 139:198-206.
40. Taketani S., Adachi Y., Nakahashi Y. Regulation of the expression of human ferrochelatase by intracellular iron levels. Eur. J. Biochem. 2000, 267:4685-4692.
41. Thompson J.D., Higgins D.G., Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22:4673-4680.
42. Tsugane S., Sasaki S., Kobayashi M., et al. Dietary habits among the JPHC study participants at baseline survey. Japan Public Health Center-based Prospective Study on Cancer and Cardiovascular Diseases. J. Epidemiol. 2001, 11:S30-S43.
43. Tugores A., Magness S.T., Brenner D.A. A single promoter directs both housekeeping and erythroid preferential expression of the human ferrochelatase gene. J. Biol. Chem. 1994, 269:30789-30797.
44. Webby C.J., Wolf A., Gromak N., et al. Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science 2009, 325:90-93.
45. Zamore P.D., Green M.R. Identification, purification, and biochemical characterization of U2 small nuclear ribonucleoprotein auxiliary factor. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:9243-9247.